Case report

Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma

Angus G. Dalgleish a,*, Emma McLean b, Nirav Patel a, Najib Rahman c

a St George’s University Hospital, London, UK
b Oncology, Haematology and Cellular Pathology Guy’s and St Thomas’ NHS Foundation Trust, London, UK
c Oxford University Hospitals, Oxford, UK

ARTICLE INFO

Keywords:
Mesothelioma
Anti-inflammatory
Immunotherapy
IMM-101-015

ABSTRACT

A 64 year old male heating engineer was investigated for a persistent cough and found to have epithelioid mesothelioma with pleural effusion, lung nodules and increased thoracic lymph nodes. He declined standard of care treatment following his own research and he was enrolled in a named patient programme of IMM-101. He was advised to correct his low vitamin D3 level and to start using anti-inflammatories such as aspirin, bromelain and low dose Naltrexone. At review one year later a CT scan showed no change and he continued on the regimen. Four years after the diagnosis a CT scan showed that there was a modest but definite progression of the left malignant pleural thickening, and a new right-sided effusion, enlargement of several intrathoracic nodes which had been noted on the early scans. The chest wall lump eventually broke down and required local radiotherapy. He then developed abdominal pain and found to have peritoneal disease. Last year he obtained the cannabinoids CBD and THC which slowed down the disease and a CT scan after he had been on this for six months, showed that his disease was fairly stable with marginal progression.

1. Introduction

Mesothelioma is accepted to arise as a direct consequence of asbestos exposure and this often occurs several decades prior to symptoms from the progressing tumour.

Unlike several other cancer types, it does not respond well to chemotherapy and surgery is very rarely curative. In addition to chemotherapy being poorly effective in many cases of mesothelioma, it is also suspected of hastening the progression of the tumour in some circumstances, a feature which is seen with some immunotherapy treatments in a minority of patients.

2. Case presentation

A 64 year old male heating engineer was investigated for a persistent cough and found to have with a pleural effusion, lung nodules and increased thoracic lymph nodes. Biopsy revealed an epithelioid mesothelioma (Fig. 1). He declined standard of care treatment following his own research and he was enrolled in a named patient programme of IMM-101 and he was advised to correct his low vitamin D3 level and to start using anti-inflammatories, such as aspirin, bromelain and low dose Naltrexone (LDN). IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense, which enhances the innate immune response and dendritic cell maturation and which has been shown to induce clinical responses in melanoma patients [1] and to increase survival in a randomised study in pancreatic cancer [2]. Naltrexone has been found to be a strong antagonist of TLR9 which is commonly over-expressed in chronic inflammation and several tumour types [3]. IMM-101 was given intradermally in the deltoid area at regular intervals initially every months with no significant toxicities apart from a local reaction at the site of injection.

At review one year later the CT scan showed no change and he continued on the regimen. At a review three years further on, his CT showed slow progression (Fig. 2a). Osteoporosis was also noted and he was started on Zoledronic acid which is of interest as it has innate immune stimulatory properties enhancing gamma delta T-cell activity [4].

Four years after the diagnosis he presented with an enlarging chest wall lesion where the original biopsy had been performed (Fig. 2b). A CT scan showed that there was a modest but definite progression of the left malignant pleural thickening, and a new right-sided effusion with...
peritoneal nodularity with enlargement of several intrathoracic nodes which had been noted on the early scans.

The chest wall lump eventually broke down and responded to local radiotherapy. He then developed abdominal pain and was found to have peritoneal disease (Fig. 2c).

Following radiotherapy to his chest wall disease he took no other treatment, apart from a cannabis oil preparation, which he felt improved his symptoms following radiotherapy. CT scans from baseline to 65 months are shown (Fig. 2 a-c).

3. Discussion

The pathogenesis of mesothelioma is a very low grade chronic inflammatory reaction to the asbestos fibres, which over many years leads to collective mutations leading to the mesothelioma.

The importance of chronic inflammation and cancer is well known [5] and the pathogenic association is that chronic inflammation suppresses cell mediated immunity and enhances angiogenic and tumour growth factors. In this environment, random mutations are much more likely to survive and progress than in non-inflamed environments. An example of this is the enhanced development of colon cancer in patients with ulcerative colitis. The chronic inflammation and reduce immune surveillance allow a mutated gene (eg ras) to survive and develop further mutations, aided by growth factors.

On the basis of the known pathogenesis of mesothelioma we proposed our immune-modulatory and anti-inflammatory based programme. IMM-101 enhances the innate immune response as well as inhibiting Th-2 responses. LDN inhibits TLR-9 expression and inflammatory cytokines, such as IL-6. This would reduce the inflammation drive and enhance immunity and hence reduce the inflammatory driven progression of carcinogenesis. This case suggests that this approach should be trialled in similar cases of mesothelioma, particularly in the third of patients with mesothelioma who, like our patient, refuse standard surgery and chemotherapy options.

The patient gave his full written consent for this report and is keen that others can benefit from this treatment.

Declaration of competing interest

Prof Angus G Dalgleish is a member of the scientific advisory board of Immodulon who provided IMM-101 for this patient on a named patient programme. IMM-101-015.

Acknowledgements

Prof Angus G Dalgleish is supported in this work by a grant from the ICVI (registered charity no 1080343).

References